Compare CMCO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCO | PRTA |
|---|---|---|
| Founded | 1875 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.7M | 495.8M |
| IPO Year | 1996 | N/A |
| Metric | CMCO | PRTA |
|---|---|---|
| Price | $20.52 | $9.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $35.00 | $18.86 |
| AVG Volume (30 Days) | 210.9K | ★ 696.1K |
| Earning Date | 02-09-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $977,994,000.00 | $11,786,000.00 |
| Revenue This Year | $5.60 | N/A |
| Revenue Next Year | $4.23 | $819.08 |
| P/E Ratio | $152.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.78 | $4.32 |
| 52 Week High | $37.81 | $16.67 |
| Indicator | CMCO | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 75.15 | 43.97 |
| Support Level | $17.13 | $8.65 |
| Resistance Level | $19.41 | $9.34 |
| Average True Range (ATR) | 0.74 | 0.36 |
| MACD | 0.20 | -0.00 |
| Stochastic Oscillator | 76.85 | 42.28 |
Columbus McKinnon Corp is a designer, manufacturer, and marketer of intelligent motion solutions, including motion control products, technologies, automated systems, and services that efficiently and ergonomically move, lift, position, and secure materials. Its key products include hoists, crane components, precision conveyors, actuators, rigging tools, light rail workstations, and digital power and motion control systems. The company's targeted market verticals include general industries, process industries, industrial automation, and e-commerce/supply chain/warehousing among others. Geographically, the company generates a majority of its revenue from the United States and the rest from Germany, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.